Paolo Tarantino, MD, PhD, of Dana-Farber Cancer Institute and Harvard Medical School, and Andrew W. Hahn, MD, of The University of Texas MD Anderson Cancer Center, sit down with Chandler H. Park, MD, MSc, FACP, of Norton Cancer Institute, to discuss the latest abstracts in breast and prostate cancers presented during the 2026 ESMO Congress.
Andy Hahn, MD, a resident at the University of Utah School of Medicine, discusses therapy for patients with prostate cancer whom neither docetaxel or abiraterone acetate (Zytiga) is an option.
Andy Hahn, MD, resident, University of Utah School of Medicine, discusses abiraterone acetate (Zytiga) versus docetaxel in the treatment of patients with prostate cancer.
Andy Hahn, MD, resident, University of Utah School of Medicine, discusses patient selection for abiraterone acetate (Zytiga) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC).
